July 9, 2003
Treatments for multiple sclerosis are aimed at preventing the progression of the disease and long-term disability. But current medications require painful daily injections. A local neurologist is participating in the clinical trial of a promising new treatment that is only taken once a year, for five days in a row.
Maria Rios is in the early stages of MS and she hasn't yet received the standard drug treatments to slow its debilitating effects. But she is participating in a study of Campath 1H. Las Vegas neurologist Steven Glyman is helping with the Southern Nevada portion of this national trial.
Dr. Glyman says, "These are new medications, they're monoclonal antibodies which are antibodies custom designed in a laboratory. They're given to block and to work on different parts of the immune system to try to help people with MS."
Campath 1H targets destructive white cells that destroy the protective covering of nerves. The drug can potentially stop the disease in it's tracks. And, it's only taken once a year, for five days in a row.
Dr. Glyman says, "It's a big difference in terms of the potential quality of life and hopefully the effectiveness of these medicines will be superior to what we have on the market."
To participate in the trial, you must be diagnosed with MS for less than three years. And it must be relapsing or remitting. For more information, call Dr. Glyman's office at 731-9111.
There is also a second drug on trial, CTLA 4ig, which requires that
a person be diagnosed with MS for at least ten years. There's an ongoing
recruitment for both studies, which are based locally in Henderson.
Copyright © 2003, WorldNow and KLAS